Compare Citius Pharmaceuticals Inc (CTXR) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs SiTime Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while SiTime Corporation trades at $694.89 (market cap $20.05B). The key difference: SiTime Corporation is far larger — about 1002× Citius Pharmaceuticals Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SITM | |
|---|---|---|
Market Cap | $20.01M | $20.05B |
Sector | Health | Technology |
52-Week High | $1.82 | $901.60 |
52-Week Low | $0.48 | $212.77 |
Enterprise Value | $16.23M | $19.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
SiTime Corporation (SITM) trades at $697.50, up 1.09% with strong bullish technical signals and consistent earnings beats. The stock shows robust revenue growth, expanding margins, and positive analyst sentiment with a $870 consensus price target. Recent Q2 2026 results exceeded expectations with 127% revenue growth, driven by AI infrastructure demand and the Renesas acquisition.
Outlook remains positive with AI timing growth as the key catalyst, though premium valuation and integration risks warrant caution. The stock offers significant upside potential from current levels but faces execution risks in scaling operations and maintaining margin expansion amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
